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Background: Lung transplantation (LTx) is a life-saving treatment for patients with end-stage lung disease; however, the shortage 
of donor lungs has been a major limiting factor to increasing the number of LTx. Growing experience following LTx using donor 
lungs after cardiac death (DCD) has been promising, although concerns remain. The purpose of this study was to develop a DCD 
lung harvest model using an ex vivo lung perfusion (EVLP) system and to assess the function of presumably damaged lungs harvested 
from the DCD donor in pigs.
Methods: The 40 kg pigs were randomly divided into the control group with no ischemic lung injury (n=5) and the study group 
(n=5), which had 1 hour of warm ischemic lung injury after cardiac arrest. Harvested lungs were placed in the EVLP circuit and 
oxygen capacities (OC), pulmonary vascular resistance (PVR), and peak airway pressure (PAP) were evaluated every hour for 4 
hours. At the end of EVLP, specimens were excised for pathologic review and wet/dry ratio.
Results: No statistically significant difference in OC (P=0.353), PVR (P=0.951), and PAP (P=0.651) was observed in both groups. 
Lung injury severity score (control group vs. study group: 0.700±0.303 vs. 0.870±0.130; P=0.230) and wet/dry ratio (control 
group vs. study group: 5.89±0.97 vs. 6.20±0.57; P=0.560) also showed no statistically significant difference between the groups.
Conclusions: The function of DCD lungs assessed using EVLP showed no difference from that of control lungs without ischemic 
injury; therefore, utilization of DCD lungs can be a new option to decrease the number of deaths on the waiting list.
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INTRODUCTION
Lung transplantation (LTx) is a well-known life-saving 
therapy for many end-stage lung diseases. The utilization 
rate of the donor lungs are reported as low as 6.7%(1), and 
low rate of utilization is responsible for the increased mor-
tality of the patients on the waiting lists(2). There has been 
some strategies to increase the number of LTx around the 
world which include expanding the use of extended donor 
criteria(3), living donor lobar LTx(4), ex vivo lung perfu-
sion (EVLP)(5), and use of lungs donated after cardiac 
death (DCD)(6-8). Among these strategies, use of DCD 
lungs is gradually getting the spotlight to resolve the prob-
lem of donor lung shortage although the use of DCD lungs 
may lead to higher prevalence of primary graft dysfunction, 
bronchiolitis obliterans, and mortality compared with using 
a heart beating donor lungs(6).
Kootstra et al.(7) classified DCD into four categories ac-
cording to so called Maastricht category. Category I (dead 
on arrival to the hospital) and II (failed resuscitation) corre-
spond to uncontrolled donors. Category III (awaiting cardiac 
arrest) and IV (cardiac arrest in a brain death donor) corre-
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spond to controlled donors(7). When such DCD lungs are 
considered as donors, an issue of proper assessment of lung 
function is imperative. EVLP is a method to evaluate the 
lungs that are rejected due to poor blood gas(5,8), or can 
be used to assess DCD lungs by measuring the hemody-
namics and oxygenation capacity.
The purpose of this study was to assess the harvested 
lungs from DCD donor pig using EVLP and prepare for the 
future utilization of organs from DCD in human LTx.
MATERIALS AND METHODS
1. Animal
All surgical procedures and animal care were provided in 
accordance with the Laboratory Animals Welfare Act, the 
Guide for the Care and Use of Laboratory Animals, and the 
Guidelines and Policies for swine Survival Surgery provided 
by the Institutional Animal Care and Use Committee in 
Yonsei University Health System.
Ten 40 kg Yorkshire female pigs (XP bio, Seoul, Korea) 
were randomly divided into two groups. They were sedated 
with 5 mg/kg of Tiletamine/Zolazepam (Zoletil, Virbac, 
Carros, France) and 2 mg Xylazine (Rompun, Bayer, Seoul, 
Korea) intramuscularly. Endotracheal intubation with 8 mm 
diameter tube and foley catheter was inserted. Pigs were anes-
thetized with isoflurane (Forane, JW Pharmaceutical, Seoul, 
Korea). The ventilator was set in a volume control mode with 
tidal volume of 10 mL/kg, positive end expiratory pressure 
(PEEP) of 5 cmH2O, respiratory rate of 16∼18 breaths per 
minute, and FiO2 1.0 until the time of cardiac arrest. 
In control group (n=5), the lungs had no ischemic injury. 
After sternotomy, pericardium is opened and 15,000 U of 
heparin (JW Pharmaceutical) was injected into the main 
pulmonary artery (MPA). A purse string suture was made 
in the MPA with Prolene 4-0 (Ethicon, Peterborough, ON, 
Canada) and a 20 Fr. foley catheter was inserted. After li-
gating superior and inferior vena cava, aorta was cross 
clamped and left atrial (LA) appendage incised as the 4oC 
Perfadex preservation solution (Vitrolife, Göteborg, 
Sweden) 60 mL/kg was flushed into MPA from the height 
of 30 cm. After the flushing, heart was excised and retro-
grade perfusion with 500 mL of Perfadex into the left 
atrium. While maintaining airway pressure to 15 cmH2O 
and FiO2 of 0.5, the trachea was clamped and the lungs were 
excised. LA cuff was designed to match with the size of 
the funnel shaped LA cannula (Vitrolife). and was sutured 
with Prolene 4-0, and pulmonary artery (PA) cannula 
(Vitrolife AB) was inserted into MPA and tied with heavy 
silk (Ethicon). Tracheal tube was inserted in the airway 
avoiding the collapse of the lungs.
In the study group (n=5), a vertical subxiphoid incision 
was made after the animal was anesthetized and atrial fi-
brillation was induced by 9 V electrical shock and waited 
for the cardiac arrest. After 1 hour of cardiac death, a ster-
num and pericardium was opened and 15,000 U of heparin 
was injected into MPA and cardiac massage was performed 
to circulate heparin. The following procedures were same 
as in the control group.
2. Preparation of EVLP system
The EVLP system consists of mechanical ventilator 
(Hamilton-C2, Hamilton Medical AG, Bonaduz, Switzerland) 
and centrifugal pump (Rotaflow, Maquet Cardiopulmonary 
AG, Hirrlingen, Germany) to circulate the perfusate. Mixed 
gas (6% oxygen, 8% CO2, 86% nitrogen gas) was supplied 
as the perfusate passed through the membrane oxygenator 
(Quadrox PLS oxygenator, Maquet Cardiopulmonary AG) 
to deoxygenate before the perfusate is recirculated into the 
PA. Leukofilter was placed immediately before entering the 
PA and heat exchanger (HU 35, Maquet Cardiopulmonary 
AG) was connected to the membrane oxygenator (Fig. 1). 
The perfusate used was 1,500 mL of Steen solution (Vit-
rolife AB) mixed with 10,000 U heparin (JW Pharmaceut-
ical), 500 mg cefazolin (Yuhan Corp., Seoul, Korea), and 
500 mg of methylprednisolone (Dong-A pharmaceutical, 
Seoul, Korea). 
3. Management of EVLP system
Harvested lungs were placed in a specially designed 
chamber (XVIVO chamber, Vitrolife AB) and both PA and 
LA cannula were connected to the system avoiding the air 
in the circulation. Circulation was started slowly with 150 
mL/min at 20oC, and was slowly increased to perfusate tem-
perature of 37oC over a period of 30 minutes. After 20 mi-
nutes of circulation, ventilation was started and perfusion 
flow was gradually increased. At the same time, 0.5 L/min 
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Fig. 1. Schematic diagram of ex 
vivo lung perfusion (EVLP) model. 
EVLP system consists of mechanical 
ventilator, centrifugal pump, heat- 
exchanger, and the perfusate deo-
xygenate as it passes through the 
membrane gas exchanger. Perfusate 
is infused into pulmonary artery 
through leukocyte depletion filter 
and stored in a hardshell reservior. 
Perfusate in the reservoir circulates 
continuously by the centrifugal pump.
of mixed gas was insufflated to the membrane oxygenator, 
and gas flow was adjusted to maintain PCO2 between 35 and 
45 mmHg. As the perfusate temperature reached 37oC and 
cardiac output of 40% expected, perfusion flow was in-
creased upto 1,500 mL/min. Ventilator setting was as fol-
lowing; tidal volume of 7 mL/kg, respiration rate of 7 
breaths per minute, PEEP of 5 cmH2O, and FiO2 of 0.21. 
During the entire period of EVLP, LA pressure was main-
tained between 3∼5 mmHg and PA pressure between 10∼
15 mmHg and this was possible by adjusting the level of 
the reservoir. To maintain the contents of the perfusate as 
constant as possible, 100 mL of Steen solution was ex-
changed every hour for a total of 500 mL during the 
experiment. 
4. Evaluation of the EVLP lungs
The initial time of the evaluation was set to a point when 
the cardiac output reached 40% and then measured every 
hour by measuring the functional parameters. Ten minutes 
prior to measurement, recruitment maneuver was done twice 
to an airway pressure of 25 mmHg to avoid atelectasis in 
FiO2 1.0. 
Measured parameters were oxygen capacity ([LA perfu-
sate PO2–PA pefusate PO2]/FiO2 [mmHg]) calculated using 
arterial blood gas analysis, pulmonary vascular resistance 
(PVR) ([PA pressure-LA pressure]×80/PA flow [dynesㆍ
sec/cm5]), and peak airway pressure (PAP) (cmH2O).
After 4 hours of EVLP, lung specimen from anterior and 
posterior portion of right lower lobe was resected for the 
pathologic evaluation. The specimens were fixed in 10% 
buffered formalin and stained by hematoxylin and eosin 
(H&E). Lung injury severity (LIS) was scored according to 
alveolar capillary congestion, hemorrhage, infiltration, or 
aggregation of neutrophils in the air space or the vessel wall, 
and thickness of the alveolar wall/hyaline membrane for-
mation. Each component was graded on a scale from 0 
(minimal damage) to 4 (maximal damage). The average 
sum of each field score was compared among groups(9).
Wet/dry weight ratio was examined by weight difference 
before and after storage in 80oC oven for 72 hours.
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Fig. 2. Comparison of oxygen capacities during 4 hours of ex vivo
lung perfusion (EVLP). The level of oxygen capacity was higher
in the study group than in the control group during the 4 hours
of EVLP.
Fig. 3. Comparison of pulmonary vascular resistances during 4 
hours of ex vivo lung perfusion (EVLP). Pulmonary vascular 
resistance was higher in the control group, although it did not show
statistically significant difference. As the EVLP prolonged, 
pulmonary vascular resistance slightly increased, which was more 
apparent in the study group.
Fig. 4. Comparison of peak airway pressure during 4 hours of ex
vivo lung perfusion (EVLP). The peak airway pressure of in the
study group was higher during the entire period of EVLP but did
not show statistically significant difference. The peak airway 
pressures in both groups increased sharply after 2 hours, which
suggested progression of pulmonary edema.
5. Statistics
For comparison of the functional parameters such as oxy-
gen capacity, PVR, and PAP, a repeated measures analysis 
of variance was performed. For comparison of wet/dry ratio 
and LIS, a Mann-Whitney test was performed. P-value less 
than 0.05 was considered statistically significant.
RESULTS
The level of oxygen capacity was higher in the study 
group than in control group every hour, but it was statisti-
cally insignificant throughout 4 hours period (P=0.353). 
Over time, the levels of oxygen capacity gradually decreased 
but remained relatively stable during the entire period of 
EVLP in both groups (Fig. 2).
PVR was higher overall in the control group than in the 
study group, but this also did not show a statistically sig-
nificant difference (P=0.951). As time went by, PVR had 
a tendency to increase slightly, which was more apparent 
in the study group (Fig. 3).
During the 4 hours assessment period, the PAP in the 
study group was always higher than the control group, but 
did not show statistically significant difference (P=0.651). 
For the first 2 hours during EVLP, the PAPs in both groups 
remained stable, but increased sharply thereafter (Fig. 4).
LIS was 0.700±0.303 in control group and 0.870±0.130 
in study group, with no statistically significant difference 
(P=0.230). Wet/dry ratio was 5.89±0.97 in the control 
group and 6.20±0.57 in the study group, but these values 
also did not statistically significant difference (P=0.560).
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DISCUSSION
Donation after brain death (DBD) has traditionally pro-
vided all lungs for LTx. However, since the number of do-
nor lungs are far below the numbers on the waiting list, the 
lung transplant professionals must explore donation from a 
marginal donors(3) or DCD(10,11). The lungs harvested 
from DBD have a high chance of lung injury from the 
process of brain death or from the prolonged intensive care 
prior to organ harvest, and the marginal donor lungs may 
lead to higher incidence of ischemia–reperfusion injury, ac-
counting for as high as 30% during the perioperative peri-
od(12). 
Since the first nonheart-beating donor lung was success-
fully transplanted in human after intrapleural topical cool-
ing(10), the United Network for Organ Sharing presented 
a short-term outcomes of LTx from DCD donors from 2004 
to 2009, and concluded that DCD lung recipient’s survival 
rates were not much different than the survival rates from 
brain dead donors(13). Snell et al.(14) reported acceptable 
early outcomes with a mean survival time of 311 days in 
controlled DCD lungs that were transplanted, and De 
Oliveira et al.(11) reported a long-term outcomes of all 
DCD donor lungs from 1993 to 2009, and showed equal sur-
vival rates from DCD donors to that from brain dead 
donors. However, a concern that DCD lung may be inferior 
to that of brain dead donors have been a barrier in increas-
ing the number of transplantation from the DCD donors. 
Another barrier to DCD lungs is a concept that DCD lungs 
should undergo evaluation of the lungs by EVLP assessment 
prior to deciding LTx(5). A great portion of lungs harvested 
from DCD lungs might be in a similar status as to a brain 
dead donor lungs but the concept that they should be eval-
uated with the means of EVLP assessment hinder them 
from being more frequently used.
EVLP not only allows a visual inspection of the explanted 
lungs, but it can measure hemodynamic and aerodynamic 
data, and gas exchange capacity(15). Another important ad-
vantage is that during the normothermic perfusion, active 
metabolic function is maintained, which provides an oppor-
tunity for continued assessment of the organ during the 
EVLP, or have a chance to recover with the help of anti-
oxidants(16) or gene transfer factors(17) that have effect 
during the warm perfusion. Cypel et al.(18) have developed 
a strategy of EVLP that allowed optimal PVR, airway pres-
sure, and oxygen capacity throughout the 12-hour preserva-
tion period. However, Mason et al.(19) has shown excellent 
early graft function using DCD lungs that were not placed 
on EVLP and therefore, advocated expanded usage of DCD 
lungs without routine use of EVLP. In this study, functional 
variables such as oxygen capacity, PVR, and PAP revealed 
no difference between the two groups. Although LIS and 
wet/dry ratio were higher in the study group, lung function 
remained similar to the heart beating donor lungs. 
The most common postoperative complication immedi-
ately following LTx from brain death donor is graft dys-
function as it may also be the same for the DCD lungs. 
However, experimental evidence has shown less chance of 
ischemia-reperfusion injury in DCD lungs(20) as demon-
strated by high PO2/FiO2 ratio and a low primary graft dys-
fuction scores.
The relationship between the incidence of airway compli-
cations and bronchiolitis obliterans syndrome (BOS) is not 
yet certain due to the limited experience with the DCD 
LTx(6), and a novel strategies in the future study include 
premortem treatment of DCD donors with N-acetyl cys-
teine, surfactant, nitroglycerin, or nitric oxide just prior to 
implantation and compare the incidence of ischemia re-
perfusion injury and the incidence of BOS during the fol-
low-up period(16). As the legal issue of providing the recip-
ients with the DCD lungs is solved, more patients can be 
saved as shown by the report that using the DCD donors 
has increased the number of LTx by 16% beyond the DBD 
LTx performed over the same period(14).
CONCLUSION
Our findings suggest that the utilization of lungs from 
DCD after the assessment by EVLP can expand the donor 
pool for LTx, and DCD lung donation can be a new option 
to decrease the number of death on the waiting list. 
However, further studies with the large animals are neces-
sary in order to apply the actual LTx using DCD donor 
lungs in humans. 
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